Aggressive Lymphomas
News
Risk of second cancers in Hodgkin lymphoma survivors
Survivors of childhood Hodgkin lymphoma (HL) have a 14-fold higher risk of second cancers compared to the general population, according to new...
Conference Coverage
Checkmate 436: Two-drug combo is ‘promising’ for PMBCL
SAN DIEGO – The early results suggest a high overall response to the drug combination.
Conference Coverage
ECHELON-2: BV-CHP boosts survival in PTCL
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
CHMP recommends BV+AVD for Hodgkin lymphoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Combo bests standard care in younger CLL patients
SAN DIEGO—In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger...
Conference Coverage
Ibrutinib-rituximab ‘new standard of care’ in younger CLL patients
SAN DIEGO – Survival and safety outcomes were better with ibrutinib and rituximab than with the FCR regimen.
News
Mutation confers resistance to venetoclax in CLL
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients...
News
Two-drug combo deemed ‘very promising’ for PMBCL
SAN DIEGO—Nivolumab plus brentuximab vedotin may be a new treatment option for patients with relapsed/refractory primary mediastinal large B-cell...
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Conference Coverage
Phase 3 study confirms biosimilarity of PF-05280586 with rituximab
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.